U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV …
New RSV Vaccine Label Updated to Note Risk of Rare Guillain …
3 days ago · The Food and Drug Administration (FDA) will now require labeling changes for 2 respiratory syncytial virus (RSV) vaccines to warn of the potential risk of Guillain-Barré …
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
4 days ago · The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days …
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in ... - Nasdaq
Aug 12, 2024 · Pfizer Inc. today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial MONeT, evaluating two doses of …
Pfizer sales of RSV vaccine ebb, but company gains market share
Oct 29, 2024 · Sales of Pfizer’s new vaccine for respiratory syncytial virus were lower in the third quarter than during the same period last year, but the company pointed to signs of growing …
MONeT: RSV Vaccine Abrysvo Meets Endpoints in Adults 18 to 59 …
Apr 11, 2024 · Positive topline data were announced from the phase 3 MONeT trial evaluating a single dose of Abrysvo ® (respiratory syncytial virus vaccine) in adults 18 to 59 years of age at …
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged …
Oct 22, 2024 · Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, and adults 18 and older at increased risk of lower respiratory tract disease …
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food …
Pfizer builds case for RSV shot with data from …
Aug 12, 2024 · Pfizer on Monday said its RSV vaccine Abrysvo led to strong immune responses in immunocompromised adults given the shot in a late-stage study. The results came from a …
Pfizer reports top-line results from Phase III RSV vaccine trial
Mar 1, 2024 · Pfizer has reported top-line results from the Phase III RENOIR clinical trial of its respiratory syncytial virus (RSV) vaccine, ABRYSVO, for RSV-linked lower respiratory tract …